A Department of Health and Human Services spokesperson called the move "a radical departure from past practices." ...

Pliant Therapeutics will cut 45% of its workforce in a sweeping restructuring effort aimed at extending its cash runway, the ...

The FDA has freed Amgen’s mysterious early-stage obesity asset from a clinical hold, with the phase 1 study now enrolling ...

Tempus AI has announced that it is using the TIME Network to support Phase I trials and expedite site activation and ...

Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 billion over the coming years.

The FDA is expected to decide on treatments for bullous pemphigoid, hereditary angioedema, HIV PrEP, ovarian cancer, and RSV.

Shares of Arvinas fell after the biotechnology company ended plans for two Phase 3 trials as part of its collaboration with Pfizer, and said that it would cut about a third of its workforce. The stock ...

Avacopan has been shown to work well in a real-world setting in a much broader group of people with vasculitis than was studied in the phase 3 trial that led to its approval.

Verona Pharma’s Ohtuvayre generated $71.3M in Q1'25 sales, signaling blockbuster potential. Read more on VRNA’s upcoming ...

According to CEO Daniel Vitt, clinical and disability-related outcomes are more relevant than brain volume change for drug ...

The FDA has completed its 30-day review of an application for Hepzato in combination with standard of care in liver-dominant ...

Cereno Scientific reported a successful meeting with the FDA on the design of a future clinical trial for its PAH therapy ...